Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
137.96
+3.30 (2.45%)
At close: Jan 29, 2026, 4:00 PM EST
139.99
+2.03 (1.47%)
After-hours: Jan 29, 2026, 7:33 PM EST
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
$1,490,389
Profits / Employee
$237,778
Market Cap
13.76B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 36,830 |
| Viatris | 32,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,561 |
| Elanco Animal Health | 9,450 |
| Amneal Pharmaceuticals | 8,300 |
| Alkermes | 1,800 |
| Hims & Hers Health | 1,637 |
NBIX News
- 3 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PRNewsWire
- 8 days ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - PRNewsWire
- 14 days ago - Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PRNewsWire
- 17 days ago - Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
- 24 days ago - Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 5 weeks ago - Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage - Benzinga
- 5 weeks ago - Neurocrine's movement disorder treatment fails late-stage trial - Reuters